Literature DB >> 20460908

The role of cytokines in non-alcoholic fatty liver disease.

Herbert Tilg1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is commonly associated with obesity and diabetes, and is characterized by insulin resistance (IR). Cytokines and adipocytokines (i.e. mediators mainly derived from adipose tissue) play a major role in the orchestration of inflammatory processes throughout the body. In addition, many of these mediators are able to regulate very diverse functions including inflammatory, immune and metabolic processes such as IR. The pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) are critically involved in the pathophysiology of various aspects of human NAFLD. The importance of TNF-alpha in human and animal fatty liver diseases, both due to genetic manipulation and overnutrition, has been demonstrated. Furthermore, neutralization of TNF-alpha activity improves IR and fatty liver disease in animals. IL-6 is derived from many cells throughout the body including adipocytes. Serum levels of this cytokine correlate remarkably well with the presence of IR, and adipose tissue-derived IL-6 has been shown to regulate hepatic IR via upregulation of SOCS3. Adiponectin is a potent TNF-alpha-neutralizing and anti-inflammatory adipocytokine, and in vitro and experimental animal studies have proven the importance of this mediator in counteracting inflammation and IR. Anti-inflammatory effects of adiponectin are mediated via suppression of TNF-alpha synthesis as well as induction of anti-inflammatory cytokines such as IL-10 or IL-1 receptor antagonist. Therefore, the balance between pro- and anti-inflammatory acting cytokines/adipocytokines appears to play a key role in hepatic and systemic insulin action, and they are supposed to have important functions in the development of NAFLD. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460908     DOI: 10.1159/000282083

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  77 in total

1.  Piperonal prevents high-fat diet-induced hepatic steatosis and insulin resistance in mice via activation of adiponectin/AMPK pathway.

Authors:  X Li; Y Choi; Y Yanakawa; T Park
Journal:  Int J Obes (Lond)       Date:  2013-05-07       Impact factor: 5.095

Review 2.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  Hydroxyeicosapentaenoic acids and epoxyeicosatetraenoic acids attenuate early occurrence of nonalcoholic fatty liver disease.

Authors:  Chunjiong Wang; Wenli Liu; Liu Yao; Xuejiao Zhang; Xu Zhang; Chenji Ye; Hongfeng Jiang; Jinlong He; Yi Zhu; Ding Ai
Journal:  Br J Pharmacol       Date:  2017-06-09       Impact factor: 8.739

Review 4.  The emerging role of mast cells in liver disease.

Authors:  Veronica Jarido; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Joanne Thomson; Kristen Stephenson; Heather Francis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-05-04       Impact factor: 4.052

5.  Non-alcoholic fatty liver disease in patients with migraine.

Authors:  Asuman Celikbilek; Mehmet Celikbilek; Aylin Okur; Serkan Dogan; Elif Borekci; Mustafa Kozan; Sebnem Gursoy
Journal:  Neurol Sci       Date:  2014-04-23       Impact factor: 3.307

Review 6.  Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?

Authors:  Bülent Baran; Filiz Akyüz
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 7.  The vagus nerve and the inflammatory reflex--linking immunity and metabolism.

Authors:  Valentin A Pavlov; Kevin J Tracey
Journal:  Nat Rev Endocrinol       Date:  2012-12       Impact factor: 43.330

8.  Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Rhiannon N Hardwick; April D Lake; Anika L Dzierlenga; John D Clarke; Michael J Goedken; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-12-08       Impact factor: 3.922

9.  Multiplex assay reliability and long-term intra-individual variation of serologic inflammatory biomarkers.

Authors:  Heather S McKay; Joseph B Margolick; Otoniel Martínez-Maza; Joseph Lopez; John Phair; Giovanna Rappocciolo; Thomas N Denny; Larry I Magpantay; Lisa P Jacobson; Jay H Bream
Journal:  Cytokine       Date:  2016-12-09       Impact factor: 3.861

Review 10.  Innate immune activation in obesity.

Authors:  Carey N Lumeng
Journal:  Mol Aspects Med       Date:  2012-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.